Getting Biosimilars to Market, a recent virtual panel moderated by MoginRubin’s Joy Sidhwa, examines commercial challenges facing biosimilars from both the patent and the antitrust perspectives. Joy and a panel of five prominent industry attorneys examine biologic manufacturers’ pricing and contracting tactics, patent thickets, the ongoing scrutiny by the FTC, the DOJ and the courts, and more. For information about the virtual panel, click here to read the full transcript.